Global CFTR Modulators Drug Market Size Forecast Clinical Trials Research Development Report 2026

Demand For Cystic Fibrosis Drugs Will Drive CFTR Modulators Market Says Kuick Research

NEW DELHI, April 22, 2021 /PRNewswire/ --

"Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:

• Global CFTR Modulators Market Opportunity:  > US$ 20 Billion
• Global CFTR Modulators Market Growth:  42% CAGR (2017 -2020)
• Global CFTR Modulators Market Growth In 2020:  55%
• Global CFTR Modulators Pipeline:  30 Drug
• Commercially Available Bispecific Antibodies: 4 Drugs
• Trikafta Market Share 2020: > 50%

Download Report:

https://www.kuickresearch.com/report-global-cystic-fibrosis-cftr-modulators-therapeutics-market-size-vertex-trikafta-cftr-potentiators-clinical-trials-research

"Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2026" provides comprehensive insight on clinical and non-clinical factors that are driving the global CFTR Modulators market and its impact on the global pharmaceutical market landscape. The report has been prepared in a view to deeply profile the current market trends along with the sales insight on 4 commercially available CFTR Modulators with their, market share and the clinical profile.

Cystic fibrosis (CF) is caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein, an anion channel that regulates the activity of other ion transporters and governs the hydration and viscoelastic properties of mucus in several epithelial tissues. CFTR variants that produce disease result in aberrant ion transport and mucus obstruction of the airways, leading to chronic infection, inflammation and ultimately damage progressing to respiratory failure. Over 2000 variants in the CFTR gene have been identified and greater than 300 are known to cause disease.

Earlier, the treatment of cystic fibrosis was mainly done by symptomatic therapy which has led to steady improvements in patient longevity and quality of life. Despite these advances, the median predicted survival of newborns with CF is well below that of unaffected newborns in developed countries. The advancement in research and technology has led to the development of CFTR modulators which aim to improve or restore the function of defective CFTR proteins and are effective for people with certain mutations.

Currently, four CFTR modulators including Kalydeco, Orkambi, Symdeko and Trikafta have been approved for the management of cystic fibrosis. Among all, the market is mainly dominated by Trikafta which is triple combinational regimen and has the ability to overcome the limitations of other approved therapies. Their targeted nature and high specificity to the specific mutations have led to high adoption rates in the market. In addition to this, these drugs have shown robust clinical response and have considerably improved the quality of life of patients.

The encouraging response of these drugs and high adoption rates has led to the robust research and development activities in this area. Several pharmaceutical companies including Vertex Pharmaceuticals, AbbVie, 4D Molecular Therapeutics and others are currently developing a wide range of CFTR modulators based on different mechanism of action which are present in clinical trials. In addition to this, researchers are also conducting trials to extent the use of these therapies in different mutations which will drive the market. Although these drugs have considerable benefits but the market will mainly be restrained by their high cost of treatment, which reduces their bioavailability in patients. However, the patent expiration in next 5-6 years of novel CFTR modulators will open the opportunities for the development of generic drugs whcih will further propel the growth of market.

US is currently dominating the global CFTR modulator drug market and is expected to maintain its position for next 5-6 years owing to their increase in prevalence of cystic fibrosis and the presence of large pharmaceutical sector which actively indulge in research and development activities. In addition to this, Europe and Asia-Pacific will emerge as a potential market owing to rise in research and development activities and the rapid approval of several drugs.

It is expected that CFTR modulators will hold a considerable space in the overall cystic fibrosis market mainly due to high specificity and improved quality of life of patients. In coming years, market will see a rapid approval of several CFTR modulator combinations of different mechanism of action which will also propel the growth of market. As per our analysis, the global CFTR modulator market will witness high growth rates during the forecasted period.

Contact:
Neeraj Chawla
Research Head
+91-981410366
[email protected] 
https://www.kuickresearch.com

Logo: https://mma.prnewswire.com/media/1245952/Kuick_Research_Logo.jpg